Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prolox
- Development stage
- Unknown
- Lead developer
- Percos
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Prolox is a topical formulation of minoxidil developed by Percos for the treatment of androgenetic alopecia (hair loss) in both men and women. Minoxidil is a potassium channel opener and vasodilator that stimulates hair growth by widening blood vessels and improving blood flow to hair follicles. This action prolongs the anagen (growth) phase of the hair cycle and prevents hair follicle shrinkage. Prolox is available in various strengths, including Prolox 5 (5% minoxidil) and Prolox-DS 10 (10% minoxidil).
- Brand names
- ProloxProlox 5Prolox5Prolox-5Prolox-DSProlox-DS 10Prolox-DS10Prolox-DS-10
02
Targets
SUR2B (Sulfonylurea receptor 2B)
Beyond the preview
Go deeper on Prolox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prolox.